Comparison of two types of extension tubes for people with Parkinson’s disease in advanced treatment with levodopa–entacapone–carbidopa intestinal gel infusions: a prospective, crossover quality study

Comparison of two types of extension tubes for people with Parkinson’s disease in advanced treatment with levodopa–entacapone–carbidopa intestinal gel infusions: a prospective, crossover quality study

Background Within Parkinson’s disease (PD) management, a pivotal juncture often arises when individuals with PD (PwP) necessitate advanced therapies to stabilise symptom fluctuations and reduce off-periods, which are intrinsic to living with PD. One such intervention is the infusion of duodenal levo...

Full description

Bibliographic Details
Main Authors:	Bo Biering-Sörensen, Trine Hørmann Thomsen, Louise Olsen, Mahsa Javidi, Nikolaj Folke La Cour Karottki
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-01-01
Series:	BMJ Open Quality
Online Access:	https://bmjopenquality.bmj.com/content/13/1/e002612.full

Similar Items

Clinical profile of levodopa-carbidopa-entacapone intestinal gel infusion in patients with advanced Parkinson’s disease
by: Karina A. Atanasova-Ivanova, et al.
Published: (2023-12-01)

Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
by: Mezin Öthman, et al.
Published: (2021-03-01)

Home-Based Titration with Duodenal Infusion of Levodopa-Carbidopa Intestinal Gel in People with Parkinson’s Disease: An Observational Feasibility Study
by: Trine Hørmann Thomsen, et al.
Published: (2024-01-01)

Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson’s disease: real-world experience and practical guidance
by: Dag Nyholm, et al.
Published: (2022-06-01)

Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson’s Disease Patients
by: Thomas Müller, et al.
Published: (2022-04-01)

USE OF THREE-COMPONENT LEVODOPA (LEVODOPA/CARBIDOPA/ENTACAPONE) TO CORRECT NOCTURNAL SYMPTOMS OF PARKINSON,S DISEASE
by: T. K. Kulua, et al.
Published: (2015-08-01)

Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
by: Kye Won Park, et al.
Published: (2020-09-01)

Population pharmacokinetics of levodopa gel infusion in Parkinson’s disease: effects of entacapone infusion and genetic polymorphism
by: M. Senek, et al.
Published: (2020-10-01)

Levodopa/carbidopa and entacapone in the treatment of Parkinson&rsquo;s disease: efficacy, safety and patient preference
by: Thomas M&uuml;ller
Published: (2009-01-01)

Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa/levodopa/entacapone (Stalevo&reg;)
by: Paolo Solla, et al.
Published: (2010-08-01)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01)

Development and Validation of a Robust and Efficient HPLC Method for the Simultaneous Quantification of Levodopa, Carbidopa, Benserazide and Entacapone in Complex Matrices
by: Erik Wollmer, et al.
Published: (2017-07-01)

Predictive Value of Ambulatory Objective Movement Measurement for Outcomes of Levodopa/Carbidopa Intestinal Gel Infusion
by: Gökçe Kilinçalp, et al.
Published: (2022-01-01)

Continuous 24-h Levodopa-Carbidopa Intestinal Gel Infusion After a Levodopa Holiday Suppressed Refractory Dyskinesia Despite Increasing Levodopa Dose
by: Noriko Nishikawa, et al.
Published: (2022-09-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)

Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without endoscopy in patients with Parkinson’s disease on levodopa-carbidopa intestinal gel infusion therapy
by: Yohei Mukai, et al.
Published: (2020-01-01)

Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson's disease
by: Ana Olivares, et al.
Published: (2012-03-01)

Acalculous cholecystitis associated with levodopa-carbidopa intestinal infusion therapy: A case report
by: Viviana Torres, et al.
Published: (2022-01-01)

Patient and caregiver outcomes with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease
by: Francesc Valldeoriola, et al.
Published: (2021-11-01)

Rescue Levodopa/Carbidopa Intestinal Gel for Secondary Deep Brain Stimulation Failure
by: Juan Miguel Pilar Bautista, et al.
Published: (2020-01-01)

Polyneuropathy monitoring in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel
by: K. Amande M. Pauls, et al.
Published: (2021-12-01)

Apraxia of eyelid opening might be critical for levodopa-carbidopa intestinal gel treatment
by: Hiroshi Kataoka, et al.
Published: (2020-01-01)

Xanthonychia Due to Staining From Carbidopa-Levodopa
by: Jonathan Kyle Hwang, et al.
Published: (2023-07-01)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Libo Wang, et al.
Published: (2018-07-01)

Benefits of Levodopa-Carbidopa Intestinal Gel Infusion in Patients with Parkinson’s Disease Experiencing Gait Dysfunction Following Subthalamic Deep Brain Stimulation
by: Thomas Edmund Kimber, et al.
Published: (2019-09-01)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
by: Peter A. LeWitt, et al.
Published: (2022-11-01)

Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)

Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson’s disease
by: Melanie R. Shackleford, et al.
Published: (2022-01-01)

Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?
by: Maria José Catalán, et al.
Published: (2017-09-01)

Liquid Levodopa/Carbidopa: Old Solution, Forgotten Complication
by: Nirosen Vijiaratnam, et al.
Published: (2017-09-01)

Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes
by: C. Marin, et al.
Published: (2008-12-01)

New-onset impulse control disorders after treatment with levodopa–carbidopa intestinal gel in Parkinson's disease
by: A. Contreras Chicote, et al.
Published: (2023-04-01)

New-onset impulse control disorders after treatment with levodopa–carbidopa intestinal gel in Parkinson's disease
by: A. Contreras Chicote, et al.
Published: (2023-04-01)

Parkinson’s Kinetigraph in the Selection of Levodopa-Carbidopa Intestinal Gel for Motor Fluctuations Refractory to Deep Brain Stimulation
by: Yassine Noui, et al.
Published: (2021-09-01)

Frequency of adverse events in Levodopa‐carbidopa intestinal gel treatment: A retrospective real life study.
by: Donato Melchionda, et al.
Published: (2022-09-01)

The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson’s Disease: A Systematic Review
by: Zhang XR, et al.
Published: (2020-02-01)

Predictors of Response for “Off” Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry
by: Werner Poewe, et al.
Published: (2020-06-01)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
by: Peter LeWitt, et al.
Published: (2023-01-01)

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease
by: Jason Margolesky, et al.
Published: (2018-01-01)

Clinical Response of Levodopa Carbidopa Combination in Patients with Idiopathic Parkinsonism
by: ABHIJITH LALESH MERAJOTH, et al.
Published: (2016-05-01)